Sequence information
DRAVP ID DRAVPc040
Name Zansecimab
Sequence
Molecular Formula Not Available
Condition/Disease COVID-19
Group Phase â…ˇclinical trial
Type Antibody
Description Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19). It is a humanized IgG4 isotype antibody that neutralizes phospho-Tie2 induction due to Ang2, thereby stopping angiogenesis. The mechanism behind the neutralization is due to the antibody binding with high affinity to, and inhibiting Ang2.
Active sequence/Structure
External Links
DrugBank Accession Number DB16389
Pubchem ID 434370480
CHEMBL ID CHEMBL4650486
UNII A67ZN01CAW
CAS 2415205-37-5
Reference 30701027
ClinicalTrails Information
NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
---|---|---|---|---|---|
NCT04342897 | A Study of LY3127804 in Participants With COVID-19 | Pneumonia / Coronavirus Disease 2019 (COVID‑19) Treatment | Terminated (Trial terminated for futility.) | Phase 2 | Eli Lilly and Company |